ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,127.79
      1.26%
      US Tech 100
      17,446.00
      2.17%
      Dow Jones
      38,675.68
      1.18%
      Brent Oil
      83.105
      0.41%
      Bitcoin
      63,757.77
      -0.21%
      Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. USOTC
      6. Defence Therapeutics Inc (QB) (DTCFF)

      7. Defence Therapeutics Inc (QB) (DTCFF) News

      DTCFF

      Defence Therapeutics (QB) (DTCFF)

      Defence Therapeutics Inc (QB)
      		Date:
      Sort by:
       Showing the most relevant articles for your search:USOTC:DTCFF
      DateTimeSourceHeadlineSymbolCompany
      02/16/202210:00AMInvestorsHub NewsWireDEFENCE RETAINS CATO SMS TO ADVISE ON ITS  PHASE I CLINICAL TRIAL ON ACCUTOXTM FOR BREAST CANCERUSOTC:DTCFFDefence Therapeutics Inc (QB)
      01/26/20228:49AMInvestorsHub NewsWireDefence's AccumTM-HPV vaccine formulation (AccuVAC-PT009) activates a 36-fold higher humoral response compared to Gardasil-9USOTC:DTCFFDefence Therapeutics Inc (QB)
      11/30/202112:32PMInvestorsHub NewsWireDEFENCE THERAPEUTICS VACCINES AND PROGRAM DEVELOPMENTUSOTC:DTCFFDefence Therapeutics Inc (QB)
      11/23/20218:24AMInvestorsHub NewsWireDEFENCE THERAPEUTICS CANCER VACCINE ACCUVAC-D001 MANUFACTURING TARGETS MELANOMA AND BREAST CANCERUSOTC:DTCFFDefence Therapeutics Inc (QB)
      11/09/202111:50AMInvestorsHub NewsWireDEFENCE THERAPEUTICS APPOINTS DR. RIAM SHAMMAA TO ITS BOARD OF DIRECTORSUSOTC:DTCFFDefence Therapeutics Inc (QB)
      11/03/20218:11AMInvestorsHub NewsWireVACCINE RESULTS: DEFENCE THERAPEUTICS REPORTS SUCCESSFUL COMPLETION OF ITS COVID-19 VACCINE ACCUVAC-PT001 TOXICOLOGY STUDIES IN RABBITSUSOTC:DTCFFDefence Therapeutics Inc (QB)
      10/13/20219:15AMInvestorsHub NewsWireDEFENCE THERAPEUTICS ACCUMTM VARIANTS IN VITRO STUDY INCREASES THE POTENCY OF T-DERUXTECAN ADC BY 5-FOLD ON BREAST CANCERUSOTC:DTCFFDefence Therapeutics Inc (QB)
      10/06/20219:32AMInvestorsHub NewsWireDEFENCE THERAPEUTICS PREPARES FOR PHASE I TRIAL TO TEST ITS DC CANCER VACCINE, ACCUVAC-D002, AGAINST MELANOMAUSOTC:DTCFFDefence Therapeutics Inc (QB)
      09/29/20218:30AMInvestorsHub NewsWireDEFENCE THERAPEUTICS TO FINALIZE ITS OBJECTIVES TO INITIATE A PHASE I TRIAL AGAINST BREAST CANCERUSOTC:DTCFFDefence Therapeutics Inc (QB)
      09/20/202110:01AMInvestorsHub NewsWireDEFENCE THERAPEUTICS SUCCESSFULLY ENGINEERED AND TESTED A NOVEL INTRANASAL COVID-19 VACCINE FORMULATION IN ANIMALSUSOTC:DTCFFDefence Therapeutics Inc (QB)
      09/14/20218:13AMInvestorsHub NewsWireDEFENCE THERAPEUTICS SUCCESS IN TESTING IT'S COVID-19 ACCUVAC-PT001 VACCINE IN A NON-RODENT MODELUSOTC:DTCFFDefence Therapeutics Inc (QB)
      09/07/20217:35AMInvestorsHub NewsWireDEFENCE THERAPEUTICS DEVELOPMENT PROGRAM TO ENGINEER A NEW HPV VACCINE INITIATEDUSOTC:DTCFFDefence Therapeutics Inc (QB)
      09/01/202110:39AMInvestorsHub NewsWireThe vaccination specialist is about to become popularUSOTC:DTCFFDefence Therapeutics Inc (QB)
       Showing the most relevant articles for your search:USOTC:DTCFF